A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects

NCT00857493 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
120
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Bavarian Nordic